Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) Delaware 75-3254381 (State or o ...

With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.Iovance Biotherapeutics (IOVA 7.54%) is going to finish the week strong on the stock market if its Thursday performance is any indication. Investors boosted the company's share price by almost 8%, following the initiation of coverage by an analyst who's bullish on its future. With that rise, Iovance easily eclipsed the S&P 500 index's 0.2% increase.Vast potential with melanoma drugThe analyst launching his Iovance ...

The biotech is making important breakthroughs, but is that enough? These are exciting times to be an Iovance Biotherapeutics (IOVA) shareholder. The biotech has made encouraging clinical and regulatory progress in the past year. Its most important product is helping it generate strong revenue growth, and although it has been a bit of a wild and volatile ride, its shares have performed much better than the broader market over the trailing 12-month period. It might be worth investing in the stock if the compa ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial. In my previous Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) article, I discussed the company's preparations for the FDA's impending verdict on lifileucel, their tumor-infiltrating lymphocyte ("TIL") therapy for advanced melanoma. I was expecting the ti ...

There's plenty of upside with this stock, but it might take a while to realize. Iovance Biotherapeutics (IOVA 9.30%) is a hot biotech stock for a reason: It's almost certainly going to be growing its top line at a snappy pace over the next few years, and there's no other therapy that's quite like the one it recently started to commercialize. But, like most of the companies in its group, there are a lot of caveats and tidbits of industry knowledge that you'll need to appreciate before you can feel confident ...

Investors should brace for dilution. Iovance Biotherapeutics (IOVA -0.19%) investors received great news earlier this year when the U.S. Food and Drug Administration granted it accelerated approval for the company's cell therapy treatment for advanced melanoma, Amtagvi. It gives the business a crucial product to build its operations around. Growth investors were initially bullish on the news, but in recent months, the stock has started to struggle. While there is a lot more optimism surrounding the company, ...

This company's new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace. It's been a wild roller-coaster ride for Iovance Biotherapeutics (IOVA 0.25%). In February, the stock more than doubled in price, then it fell to a 52-week low in July. The stock has since recovered and at recent prices was up 47% for the year. Can Iovance keep soaring in the years to come, or is its big gain in 2024 more likely to fizzle out? Here's a look at what to expect in the near ...

The biopharma company is proving its recently approved cancer therapy is marketable. After watching its stock fall for weeks on worries of disappointing results, Iovance Biotherapeutics (IOVA 18.64%) has vindicated itself. Shares of the young biopharma company are up 24.2% as of 11:20 a.m. ET today in response to an impressive second-quarter report. This bullish jolt could also mark the beginning of a more prolonged move higher. Iovance's Amtagvi is off to a solid start In simplest terms, caregivers are emb ...

Iovance Biotherapeutics (NASDAQ:IOVA) stock is taking a beating on Friday after the biotechnology company announced its earnings for the second quarter of the year. Iovance Biotherapeutics starts that report with adjusted earnings per share of -34 cents. That's just barely above the -35 cents per share Wall Street was expecting. It's also better than the -47 cents per share from the same period of the year prior. Revenue reported by Iovance Biotherapeutics also came in at $31.11 million. That's another beat ...

Iovance Biotherapeutics Inc IOVA stock is trading higher on Friday after the company issued upbeat guidance for 2024 and 2025 and better-than-expected second-quarter earnings. On Thursday, the cancer cell therapy maker Iovance reported second-quarter sales of $31.12 million, surpassing the consensus of $24.6 million. The company reported EPS loss of $(0.34), down from $(0.47) a year ago, beating the consensus of $(0.35). Also Read: Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For ...